Speed, complexity, and quality—it’s no longer enough to pick two.
In BioCina’s latest article, senior leaders share how the company’s unified CDMO platform eliminates traditional handoffs, enabling biotech innovators to scale smarter and reach patients faster. With operations spanning from pDNA and mRNA to blow–fill–seal and aseptic vial/syringe fill, BioCina brings true integration to biomanufacturing.
Inside the article:
- Why integration across drug substance and drug product matters more than ever
- How BioCina’s Adelaide and Perth sites now function as one global CDMO ecosystem
- What infrastructure upgrades mean for mRNA, LNP, microbial, and sterile injectables
- How a client-first approach leads to a 95% on-time, in-full delivery rate
These integration benefits combined with the myriad benefits of manufacturing in Australia, including Up to 48.5% tax rebate for clinical manufacturing, BioCina is able to offer incredible market value for its clients.
See how BioCina is helping clients move from molecule to market without missed beats.